34.22USD-4.19%Mkt Cap: —P/E: —1d ago
Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-ty…
Industry Peers
Biotechnology$139.84BUSDP/E 32.2
$85.11BUSDP/E 20.4
$69.62BUSD
$60.19BUSDP/E 39.1
$45.16BUSDP/E 19.2
$46.01BUSD
$41.76BUSDP/E 66.2
$35.67BUSDP/E 33.2
$32.46BUSDP/E 42.3
$28.53BUSD
$26.14BUSD
$25.79BUSDP/E 16.2
$20.83BUSDP/E 26.3
$19.17BUSDP/E 26.2
$17.03BUSDP/E 20.0
$16.41BUSD
$13.48BUSDP/E 17.1
$13.42BUSDP/E 187.4
$12.87BUSDP/E 264.5
$12.59BUSD
Key Statistics
Company
Market Cap—
Enterprise Value1.48B $
Revenue (TTM)98.34M $
Gross Profit-266.29M $
Net Income (TTM)-411.29M $
Revenue/Share1.675 USD
Last Price34.22 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees539
CountryGB
SectorHealthcare
IndustryBiotechnology
ISINUS00847X1046
Valuation
P/E (Trailing)—
P/E (Forward)—
PEG—
EV/EBITDA-3.27
EV/Revenue15.07
P/S—
P/B2.01
EPS (TTM)-6.43
EPS (Forward)—
52W Range
33.4831% of range35.84
52W High35.84 USD
52W Low33.48 USD
Profitability
Gross Margin-270.79%
Oper. Margin-247.07%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-34.34%
ROA-22.24%
Growth
Revenue Growth259.30%
Earnings Growth—
Cash Flow & Leverage
Operating CF-360.60M $
CapEx (TTM)—
FCF Margin-279.25%
FCF Yield—
Net Debt-586.40M $
Net Debt/EBITDA1.29
Balance Sheet
Debt/Equity3.04
Current Ratio10.22
Quick Ratio9.14
Book Value/Sh17.21 USD
Cash/Share10.34 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio—
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating—
Target (Mean)—
Target Range—
# Analysts—
Ownership
Shares Out.58.18M
Float50.02M
Insiders1.07%
Institutions112.34%
Technical
SMA 5026.18 (+30.7%)
SMA 20024.83 (+37.8%)
Beta0.59
S&P 52W Chg20.80%
Avg Vol (30d)294
Avg Vol (10d)238
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—